<DOC>
	<DOCNO>NCT01237899</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability LY2623091 multiple oral dose healthy men woman non-childbearing potential . Two cohort 16 subject participate 2 dose period . Treatment assignment double-blind LY2623091 placebo ( negative control ) , open label eplerenone ( positive control ) .</brief_summary>
	<brief_title>Multiple Dose Study Safety , Tolerability , Pharmacokinetics Effect Renal Potassium Clearance</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Are healthy men woman nonchildbearing potential determined medical history physical examination . Male subject : Nonvasectomized male subject must agree use 2 medically accept method contraception sexual partner study 90 day follow final dosing . Female subject : Female subject must nonchildbearing potential due surgical sterilization ( hysterectomy , bilateral oophorectomy tubal ligation ) menopause . They minimum 12 month without menstrual period . Perimenopausal woman 6 month without menstrual period . Have give write informed consent prior studyspecific procedure . Are reliable willing make available duration study willing follow sitespecific study procedure . Have body mass index ( BMI ) 19 32.5 kilograms/square meter ( kg/m2 ) . Have clinical laboratory test result within normal reference range population study site , test result acceptable deviation judge Investigator clinically significant . Have venous access sufficient allow blood sample per protocol . Have serum potassium level within normal range . Are nonsmokers smoker less equal 10 cigarette per day . Are currently enrol , discontinue , within 60 day inclusive , clinical trial involve investigational drug , device offlabel use approve drug , concurrently enrol type medical research judge scientifically medically incompatible study . Subjects meet criterion may enrol study dose least 60 day follow last day previous investigational trial . Have previously complete withdrawn study study investigate LY2623091 . Have history presence medical illness include limited cardiovascular , hepatic , respiratory , hematological , endocrine neurological disease , clinically significant laboratory abnormality serious medical problem would preclude study participation . Have abnormality 12lead electrocardiogram ( ECG ) , increase risk associate participation study . Are unwilling unable comply use electronic data capture system . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody , hepatitis C and/or positive hepatitis C antibody hepatitis B and/or positive hepatitis B surface antigen . Use and/or intend use medication medical condition compatible Inclusion Criterion . For medication may use `` healthyâ€Ÿ subject ( example give : preventative and/or naturopathic agent , temporary symptomrelieving medication , et cetera ) follow constraint must observe : No use vasoactive drug ( example give : diuretic , antihypertensive agent , phosphodiesterase inhibitor , erectile dysfunction medication , nasal decongestant , et cetera ) systemic glucocorticoid within 7 day first dose and/or anticipate use study . No use acetaminophen/paracetamol nonsteroidal antiinflammatory drug ( NSAIDs ) within 24 hour first dose and/or anticipate use study . Aspirin may use dos great 100 milligrams/day ( mg/day ) within 7days first dose and/or anticipate use study . No use herbal nutritional product within 7 day first dose and/or anticipate use study . Have donate blood 50 milliliter ( mL ) within last 60 day . Have average weekly alcohol intake exceed 21 unit per week and/or subject unwilling stop alcohol within 48 hour study enrollment duration study . Have abnormally high blood pressure ( supine standing ) define diastolic blood pressure great 95 millimeter mercury /or systolic blood pressure great 150 millimeter mercury , confirm least 1 repeat measurement . Have serum potassium great upper limit normal . Regularly use know drug abuse show positive finding use urinary drug screening . Consumption natural licorice and/or natural licoricecontaining product and/or grapefruit and/or grapefruit juice within 7 day first dose and/or anticipate consumption study . Consumption methylxanthinecontaining beverage and/or food ( example : coffee , tea , caffeinated soft drink , chocolate ) within 4 day first dose and/or anticipate consumption study . Are unwilling abstain saltsubstitutes contain potassium duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
</DOC>